环磷酰胺冲击治疗风湿免疫疾病的疗效探讨  

Investigation of curative effect by cyclophosphamide impact therapy for rheumatic and immunological diseases

作　　者：王利 

机构地区：[1]陕西省中西医结合医院、西安市第五医院风湿免疫科,710082

出　　处：《中国实用医药》2016年第28期27-28,共2页China Practical Medicine

摘　　要：目的探讨环磷酰胺(CTX)冲击治疗风湿免疫疾病的临床效果。方法 100例风湿免疫疾病患者,随机分为对照组与观察组,各50例。对照组采用羟氯喹、醋酸泼尼松联合甲氨蝶呤治疗,观察组采用羟氯喹、醋酸泼尼松联合CTX冲击治疗。比较两组的临床效果。结果观察组晨僵时间(2.09±0.18)h、关节压痛个数(13.4±3.2)个、关节肿胀个数(7.6±2.9)个、血沉(ESR)(40.23±25.41)mm/h、C反应蛋白(CRP)水平(19.87±8.42)mg/L均优于对照组(P<0.05)。两组关节功能分级及不良反应发生率比较差异均无统计学意义(P>0.05)。结论 CTX冲击治疗风湿免疫疾病的效果优于甲氨蝶呤,可有效缓解症状,减轻疼痛,改善临床指标,且安全性高。Objective To investigate clinical effect by cyclophosphamide（CTX） impact therapy for rheumatic and immunological diseases.Methods A total of 100 patients with rheumatic and immunological diseases were randomly divided into control group and observation group,with 50 cases in each group.The control group received hydroxychloroquine,prednisone acetate combined with methotrexate for treatment,and the observation group received hydroxychloroquine,prednisone acetate combined with CTX impact therapy.Clinical effects were compared between the two groups.Results The observation group had all better morning stiffness time as（2.09±0.18） h,articular pain as（13.4±3.2） joints,arthrocele as（7.6±2.9） joints,erythrocyte sedimentation rate（ESR） as（40.23±25.41） mm/h,and C-reactive protein（CRP） level as（19.87±8.42） mg/L than the control group（P〈0.05）.There was no statistically significant difference of joint function grading and incidence of adverse reactions between the two groups（P〉0.05）.Conclusion CTX impact therapy provides better effect than methotrexate in treating rheumatic and immunological diseases.It can effectively relieve symptom,reduce pain,improve clinical indexes with high safety.

关 键 词：风湿免疫疾病 环磷酰胺 冲击治疗 

分 类 号：R593.2[医药卫生—内科学]